MicroRNA Expression Profile in Early-Stage Breast Cancers

Overview

Journal Microrna

Publisher Bentham Science Publishers

Specialties Biochemistry
Molecular Biology

Date 2023 Oct 24

PMID 37873952

Authors

Krishna Patel

Deva Magendhra Rao

Shirley Sundersingh

Sridevi Velusami

Thangarajan Rajkumar

Bipin Nair

Akhilesh Pandey

Aditi Chatterjee

Samson Mani

Harsha Gowda

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is one of the leading causes of cancer deaths in women. Early diagnosis offers the best hope for a cure. Ductal carcinoma in situ is considered a precursor of invasive ductal carcinoma of the breast. In this study, we carried out microRNA sequencing from 7 ductal carcinoma in situ (DCIS), 6 infiltrating ductal carcinomas (IDC Stage IIA) with paired normal, and 5 unpaired normal breast tissue samples.

Methods: We have deployed miRge for microRNA analysis, DESeq for differential expression analysis, and Cytoscape for competing endogenous RNA network investigation.

Results: Here, we identified 76 miRNAs that were differentially expressed in DCIS and IDC. Additionally, we provide preliminary evidence of miR-365b-3p and miR-7-1-3p being overexpressed, and miR-6507-5p, miR-487b-3p, and miR-654-3p being downregulated in DCIS relative to normal breast tissue. We also identified a miRNA miR-766-3p that was overexpressed in earlystage IDCs. The overexpression of miR-301a-3p in DCIS and IDC was confirmed in 32 independent breast cancer tissue samples.

Conclusion: Higher expression of miR-301a-3p is associated with poor overall survival in The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) dataset, indicating that it may be associated with DCIS at high risk of progressing to IDC and warrants deeper investigation.

References

Malvia S, Bagadi S, Dubey U, Saxena S . Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017; 13(4):289-295. DOI: 10.1111/ajco.12661. View

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan K, Santhappan S . Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol. 2020; 6:1063-1075. PMC: 7392737. DOI: 10.1200/GO.20.00122. View

Hannafon B, Ding W . miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ. Am J Pathol. 2017; 188(3):542-549. PMC: 5840484. DOI: 10.1016/j.ajpath.2017.11.003. View

Schultz S, Bartsch H, Sotlar K, Petat-Dutter K, Bonin M, Kahlert S . Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. BMC Med Genomics. 2018; 11(1):80. PMC: 6147035. DOI: 10.1186/s12920-018-0403-5. View

Xiong D, Lv J, Wei K, Feng Z, Chen J, Liu K . A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases. Oncol Rep. 2017; 37(6):3297-3304. DOI: 10.3892/or.2017.5600. View

Wang F, Zheng Z, Guo J, Ding X . Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119(3):586-93. DOI: 10.1016/j.ygyno.2010.07.021. View

Jiang S, Zhang H, Lu M, He X, Li Y, Gu H . MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70(8):3119-27. DOI: 10.1158/0008-5472.CAN-09-4250. View

Chiang C, Hou M, Hung W . Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta. 2013; 1830(4):3067-76. DOI: 10.1016/j.bbagen.2013.01.009. View

Hu X, Guo J, Zheng L, Li C, Zheng T, Tanyi J . The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res. 2013; 11(3):240-50. PMC: 3606291. DOI: 10.1158/1541-7786.MCR-12-0432. View

10.

Sachdeva M, Mo Y . MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2009; 70(1):378-87. PMC: 2805032. DOI: 10.1158/0008-5472.CAN-09-2021. View

11.

Li X, Roslan S, Johnstone C, Wright J, Bracken C, Anderson M . MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene. 2013; 33(31):4077-88. DOI: 10.1038/onc.2013.370. View

12.

Blenkiron C, Goldstein L, Thorne N, Spiteri I, Chin S, Dunning M . MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007; 8(10):R214. PMC: 2246288. DOI: 10.1186/gb-2007-8-10-r214. View

13.

Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J . Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet. 2016; 62(1):15-24. DOI: 10.1038/jhg.2016.89. View

14.

Zhang K, Wang Y, Wang Y, Song Y, Zhu J, Si P . Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene. 2017; 619:10-20. DOI: 10.1016/j.gene.2017.03.038. View

15.

Kodahl A, Lyng M, Binder H, Cold S, Gravgaard K, Knoop A . Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol. 2014; 8(5):874-83. PMC: 5528529. DOI: 10.1016/j.molonc.2014.03.002. View

16.

Ng E, Li R, Shin V, Jin H, Leung C, Ma E . Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013; 8(1):e53141. PMC: 3536802. DOI: 10.1371/journal.pone.0053141. View

17.

Yoshikawa M, Iinuma H, Umemoto Y, Yanagisawa T, Matsumoto A, Jinno H . Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol Lett. 2018; 15(6):9584-9592. PMC: 5958689. DOI: 10.3892/ol.2018.8457. View

18.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

19.

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J . Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016; 107(3):326-34. PMC: 4814263. DOI: 10.1111/cas.12880. View

20.

Yerukala Sathipati S, Ho S . Identifying a miRNA signature for predicting the stage of breast cancer. Sci Rep. 2018; 8(1):16138. PMC: 6208346. DOI: 10.1038/s41598-018-34604-3. View